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Beclomethasone dipropionate (BDP) has been reformulated in a chlorofluorocarbon-free propellant, 
hydrofluoroalkane-134a (HFA), resulting in an extrafine aerosol which gives improved drug delivery to the 
airways. The objective of this 6 week, placebo-controlled study was to evaluate the clinical efficacy of 
HFA-BDP 400 pg day-l in 256 adult patients with moderate asthma. This is a lower daily dose than that 
recommended for existing BDP inhalers in current treatment guidelines for moderate asthma (NIH pub- 
lication 95-3659). Another objective was to evaluate whether delivering the 400 pg dose as four actuations 
of 50 I-18 twice daily (HFA-BDP 50 pg) provided equivalent asthma control to delivering the dose as two 
actuations of 100 pg twice daily (HFA-BDP 100 pg) without the use of a spacer or holding chamber. Both 
active treatments produced a significant change from baseline in morning peak expiratory flow (PEF), 
which was significantly larger than that in the placebo group (P 2 0.017) throughout the study. The mean 
changes from baseline in morning PEF at weeks 5-6 were 47.0 1 min-1 in the combined HFA-BDP group 
and 16.5 1 minm1 in the HFA-placebo group. The two dose strengths were statistically equivalent (P=O.O 17 
for equivalence testing). The active treatments also produced significant improvements compared with 
placebo in evening PEF, forced expiratory volume in the first second, forced expiratory flow over 25-75% 
of vital capacity, sleep disturbance scores and daily P-agonist use. The study medication was well toler- 
ated, with a low incidence of adverse events. The results from this study demonstrate that a daily dose of 
400 pg HFA-BDP (given in 50 pg and 100 pg strengths) provides dose proportionality and effective 
control in patients with moderate asthma. 
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Introduction 
Chlorofluorocarbons (CFCs) have traditionally been 
used as propellants in pressurized metered dose inhalers 
(MDIs). However, environmental concerns have led to 
the development of alternative propellants, such as 
hydrofluoroalkane- 134a (HFA), which has no ozone- 
depleting potential (1). An established corticosteroid 
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treatment for asthma, beclomethasone dipropionate 
(BDP), has been reformulated in HFA propellant. In 
this new formulation, BDP is in solution, as opposed 
to being in suspension as in the CFC formulation. This 
has resulted in an aerosol spray consisting of droplets 
that are, on average, much smaller than CFC-BDP 
suspension particles (2). Deposition studies have 
shown that this BDP extrafine aerosol delivers medi- 
cation to the lower airways, rather than to the throat, 
more effectively compared with CFC-BDP (3). HFA- 
BDP has been formulated at two different strengths: 
50 pg per inhalation (HFA-BDP 50 pg) and 100 pg 
per inhalation (HFA-BDP 100 pg). HFA-BDP 100 pg 
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delivers twice the fine particle mass of HFA-BDP 
50 ug (2), and supportive pharmacokinetic studies 
have demonstrated dose proportionality (4). 
Current national guidelines for asthma manage- 
ment recommend a stepwise strategy for inhaled 
steroid treatment (5, 6). Patients start on a dose that 
is appropriate to the severity of their asthma symp- 
toms, with the dose being adjusted as necessary to 
achieve good symptom control. For patients with 
moderate asthma, these guidelines recommend a dose 
range for BDP of 800-2000 ug day-i for existing 
inhalers. 
In view of the improved delivery characteristics of 
HFA-BDP resulting from the smaller droplet size and 
reduced jet impaction in the upper airways compared 
with CFC-BDP particles, the primary objective of 
this study was to evaluate the clinical efficacy of 
400 ug day-i HFA-BDP, a lower dose than currently 
recommended for CFC-BDP, in adults with moderate 
asthma. HFA-BDP was delivered as either four inhal- 
ations twice daily of HFA-BDP 50 pg or two inhala- 
tions twice daily of HFA-BDP 100 pg. The secondary 
objective was to evaluate the clinical equivalence of 
the two dose strengths of inhalers. 
Methods 
PATIENTS 
Patients were asthmatic, had not used inhaled steroids 
for at least 3 weeks before the trial, were aged 18-65 
years, with a diagnosis of asthma extending back at 
least 4 weeks, and were using an inhaled B-agonist for 
the relief of symptoms. In addition, an increase in 
forced expiratory volume in the first second (FEV,) of 
2 15% in response to 200 pg p- agonist was required 
for study entry. 
Other inclusion criteria included being a non- 
smoker for at least 6 months before study entry and 
demonstrating satisfactory technique in the use of an 
MD1 and proper technique in measuring peak expira- 
tory flow (PEF). Exclusion criteria included cardiac or 
pulmonary disease other than asthma, known hyper- 
sensitivity to BDP, respiratory tract infection within 
4 weeks before the study and history of alcohol or 
substance abuse. 
All patients had to be consistent with the Global 
Initiative for Asthma (GINA) classification for asthma 
of at least moderate severity, using lung function 
and/or symptom criteria (5). Entry criteria included a 
mean morning PEF between 50% and 80% of pre- 
dicted normal over the last 7 days of the 14 day run-in 
period. This population of patients would normally 
start BDP treatment on at least 800 j.tg day-i, accord- 
ing to current GINA guidelines (5). 
STUDY DESIGN 
This was a 6 week, randomized, parallel-group, 
double-blind, double-dummy, multicentre study. 
The primary efficacy variable was mean change 
from baseline in morning PEF at weeks 556 of the 
study. Secondary efficacy variables included FEV,, 
forced expiratory flow over 25-75% of vital capacity 
(FEF,,-,,%), day-time asthma symptoms, sleep distur- 
bance scores and daily use of P-agonist. Pre- and post- 
study safety assessments included blood pressure, 
pulse rate, physical examination, 12-lead electrocar- 
diography (ECG), serum chemistry, haematology and 
urinalysis. All adverse events occurring during the 
study were recorded. In patients reporting an oropha- 
ryngeal adverse event, mouth or throat swabs were 
performed for Candida culture if the investigator saw 
visible abnormalities suggestive of Candida infection. 
At a screening visit, patient characteristics, asthma 
history, relevant medical history, and the general phys- 
ical condition of the patient were recorded, and 
laboratory tests performed. A 16day run-in period 
demonstrated that patients met the criteria for at least 
moderate severity asthma, as described previously. 
Eligible patients were then randomized to receive 
HFA-placebo or 400 ug day-i HFA-BDP (QvarTM, 
3M Pharmaceuticals, St. Paul, MN, U.S.A.), either as 
four inhalations twice daily of HFA-BDP 50 pg or 
two inhalations twice daily of HFA-BDP 100 pg. 
Morning and evening PEF were recorded by 
patients in their homes using a mini-Wright peak flow 
meter. The best of three measures was recorded on the 
diary card. Day-time asthma symptom scores (wheez- 
ing, shortness of breath, chest tightness and cough) 
were recorded by the patients every evening, with each 
symptom being scored on a scale from 0 (no symp- 
toms) to 5 (symptoms prevented normal daily activi- 
ties). Sleep disturbance scores were similarly recorded 
each morning on a five-point scale from 0 (no noctur- 
nal symptoms) to 4 (symptoms prevented the patient 
from falling asleep). FEV, and FEF2j_T5% were mea- 
sured at clinic visits every 2 weeks. Also, adverse events 
were recorded and their severity and relationship to 
the study medication assessed. 
STATISTICAL ANALYSIS 
An intent-to-treat analysis was performed, carrying 
the last observation forward. The mean change from 
baseline for the primary efficacy variable morning 
PEF, over study weeks l-2, 34 and 5-6, was com- 
pared among treatment groups using analysis of vari- 
ance, with treatment, centre and treatment-by-centre 
interaction terms. Comparison of each active treat- 
ment with placebo was made. Bonferroni adjustments 
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TABLE 1. Baseline patient characteristics 
HFA-BDP 
400 pg day-l 
HFA-placebo P value 
Number of patients 
Sex 
Female, IZ (%) 
Male, y1 (%) 
Age (years), mean (SD) 
Duration of asthma, n (%) 
Unknown 
<l year 
l-5 years 
>5 years 
Baseline morning PEF 
Actual values, mean (SE) 1 min-r 
Percentage of predicted, mean (SE) 
Daily use of B-agonist, mean (SE) 
Percentage of nights without sleep 
disturbance, mean (SE) 
171 85 
79 (46.2%) 48 (56.5%) 0.169 
92 (53.8%) 37 (43.5%) 
38.9 (11.53) 41.7 (11.92) 0.073 
0.676” 
10 (5.8%) 0 
7 (4.1%) 3 (3.5%) 
79 (46.2%) 37 (43.5%) 
75 (43.9%) 45 (52.9%) 
368.7 (6.0) 350.1 (8.5) 0.075 
66.5 (0.75) 65.6 (1.07) 0.532 
2.58 (0.173) 2.53 (0.244) 0.877 
48.6 (3.2) 51.0 (4.5) 0.662 
*P value refers to difference between HFA-BDP and HFA-placebo groups for all categories of 
duration of asthma. 
were used to account for multiple testing. Similar 
analyses were performed for the secondary efficacy 
variables. Equivalence of the dose strengths was 
defined as the 90% confidence interval of the mean dif- 
ference in morning PEF contained within the interval 
of f25 1 min-I. Equivalence between HFA-BDP 50 ug 
and HFA-BDP 100 ug in mean change in morning 
PEF within f 25 1 mini was tested using the two one- 
sided tests method (7, 8). The incidence of adverse 
events was compared among treatment groups using 
Fisher’s exact test. 
Results 
PATIENTS 
A total of 256 patients were eligible for randomiza- 
tion: 171 in the 400 ug HFA-BDP group (83 using the 
50 ug inhaler, 88 using the 100 pg inhaler) and 85 in 
the HFA-placebo group. Baseline patient character- 
istics of the treatment groups were similar (Table 1). 
No significant differences were seen between groups in 
baseline pulmonary function, night-time sleep distur- 
bance scores or P-agonist use. 
Compliance was assessed by weighing the inhalers 
before and after the study. Overall compliance with the 
study drug was 88.2%, with no significant differences 
between treatment groups. 
EFFICACY 
Statistically significant (PSO.0 17) and clinically signif- 
icant, mean changes from baseline were seen for morn- 
ing PEF over 6 weeks for 400 ug day-l HFA- 
BDP delivered from either strength inhaler compared 
with HFA-placebo. At weeks 5-6 the mean changes 
from baseline were 47.0 1 min-1 in the combined 
HFA-BDP group and 16.5 1 min-1 in the HFA- 
placebo group (P < 0.001) (Fig. 1). The difference 
between the two inhaler strengths was slight, with a 
1 
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Treatment period (weeks) 
1 
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FIG. 1. Adjusted mean (& SE) change from baseline in 
morning PEF: n , HFA-BDP 400 pg day-r; 0, 
HFA-placebo. *P<O.OOl VS. placebo. 
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FIG. 2. Adjusted mean (& SE) change from baseline in 
FEV,: n , HFA-BDP 400 yg day-i; 0, HFA-placebo. 
*P<O.O06, ““WO.001 vs. placebo. 
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FIG. 3. Mean (* SE) daily P-agonist use: n , HFA- 
BDP 400 pg day-i; 0, HFA-placebo. 
90% confidence interval for the differences of from 
-9.2 to 20.7 1 min-1 at weeks 5-6. Over the 6 week study 
period statistical analysis showed the different strength 
inhalers to have equivalent efficacy (P=O.O17). 
The mean change from baseline in FEV, for the 
combined active treatment group was significantly 
larger than placebo (PIO.006) at all study weeks. The 
changes from baseline in FEV, were 0.32 1 in the 
combined HFA-BDP group and 0.09 1 in the HFA- 
placebo group at week 4 (P<O.OOl) and 0.29 and 
0.09 1, respectively, at week 6 (WO.006) (Fig. 2). Treat- 
ment with HFA-BDP resulted in a significantly 
greater reduction in daily P-agonist use compared with 
placebo (PcO.03) (Fig. 3). In the combined HFA- 
BDP group the mean number of daily uses decreased 
from 2.58 at baseline to 1.26 at weeks 5-6, whereas in 
the placebo group the number of uses only slightly 
decreased from 2.53 to 2.26. The mean percentage of 
nights without sleep disturbance was improved in the 
90, 
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FIG. 4. Mean (+ SE) percentage of nights without 
sleep disturbance per 2 week period: n , HFA-BDP 
400 ltg day-l; 0, HFA-placebo. 
HFA-BDP group compared with the placebo group 
(Fig. 4). The percentage increased from 48.6 at base- 
line to 77.1 at weeks 556 in the combined HFA-BDP 
group and from 51.0 to 54.6 in the placebo group. 
Changes from baseline for the active treatment group 
for evening PEF and FEF,,-,,, were also different 
from placebo throughout the study. In addition, 
asthma symptom scores in the active treatment groups 
demonstrated a trend towards improvement during 
the 6 weeks of the study. All of the secondary efficacy 
variables showed the effects of 400 ltg HFA-BDP 
from either strength inhaler to be similar, which sup- 
ports the finding of statistical equivalence demon- 
strated using morning PEF, the primary end-point. 
SAFETY 
All study treatments had a low incidence of adverse 
events. At least one adverse event was reported by 17% 
of patients; 14% in the HFA-BDP group and 24% in 
the HFA-placebo group. The most commonly occur- 
ring adverse events involved the respiratory system, 
with 9% of patients in the placebo group reporting 
increased asthma symptoms, compared with 1% of 
patients in each of the active treatment groups (P= 
0.007). Dysphonia related to study treatment was 
reported by two patients in the HFA-BDP 100 pg 
group and one patient in the HFA-placebo group. 
Candidiasis was not present in any of the 11 (4.3%) 
patients reporting an oropharyngeal adverse event. 
No clinically meaningful changes in serum chemistry, 
haematology, urinalysis, ECG or vital signs were 
found, and no deaths or serious adverse events were 
reported over the 6 week study period. 
Few patients withdrew from the study: 10 patients in 
the HFA-BDP 50 lt.g group, nine patients in the 
HFA-BDP 100 I-18 group and 15 in the HFA-placebo 
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TABLE 2. Number (%) of patients who withdrew from the study by reason and 
treatment 
Reason HFA-BDP HFA-BDP 
50 I% 1m !-G 
(n = 83) (n = 88) 
HFA-placebo 
(n = 85) 
Adverse event 2 (2.4%) 1 (1.1%) 5 (5.9%) 
Non-compliance 3 (36%) 2 (2.3%) 3 (3.5%) 
Lost to follow-up 2 (2.4%) 3 (3.4%) 1 (1.2%) 
Withdrawn consent 1 (1.2%) 0 3 (3.5%) 
Study site withdrawal 1 (1.2%) 1 (1.1%) 2 (2.4%) 
Protocol departure 0 2 (2.3%) 0 
Inadequate response 0 0 1 (1.2%) 
Pregnancy 1 (1.2%) 0 0 
Total 10 (12%) 9 (10.2%) 15 (17.6%) 
group. A total of eight patients withdrew owing to 
adverse events, eight because of non-compliance, and 
six were lost to follow-up (Table 2). 
Discussion 
The results of this 6 week study indicate that, in an 
adult patient population with at least moderately 
severe asthma, treatment with HFA-BDP 400 ug day-i 
was significantly more effective than HFA-placebo in 
improving asthma control. HFA-BDP 50 pg four 
inhalations twice a day was equivalent to HFA-BDP 
100 pg two inhalations twice a day in improving 
pulmonary function, reducing day-time and night- 
time asthma symptoms and, as a consequence, 
decreasing P-agonist use. The mean change from base- 
line in morning PEF at weeks 5-6 of the study was 
47.0 1 min-1 for the combined HFA-BDP group and 
16.5 1 mini for the HFA-placebo group. The improve- 
ments in morning PEF seen in the active treatment 
groups were clinically meaningful. 
Most previous studies in adult patients of inhaled 
steroid in CFC propellant have used doses of 400- 
1600 pg day-t, in line with current treatment guidelines 
(5). However, few recent studies of CFC-BDP in 
steroid-naive patients have been carried out, so it is 
difficult to make a direct comparison with the present 
study. In an early study of steroid-naive patients 
with mild to severe asthma (9), 6 weeks of treatment 
with 400 ug day-i CFC-BDP resulted in a mean 
change from baseline in FEV, of 0.8 1. In another 
study involving steroid-naive patients (lo), treatment 
for 6 weeks with the inhaled steroid budesonide 
(400 pg day-i) produced a mean change from baseline 
in morning PEF of 47 1 mini. In patients with mild 
to moderate asthma who were not steroid naive, 
treatment with CFC-BDP 400 pg day-i for 6 weeks 
produced a mean change from baseline in morning 
PEF of 11 1 mini, although the variability of the 
PEF meter is generally regarded as being at least 
+lO 1 min-1 (11). 
Current asthma treatment guidelines emphasize the 
need to give the lowest dose of inhaled steroid to gain 
asthma control and then to titrate maintenance doses 
individually (5). These guidelines recommend a dose 
range for CFC-BDP of 800-2000 pg day-l in adult 
patients with moderate asthma. This study showed a 
significant clinical improvement in the population 
using HFA-BDP 400 pg day-r. The dose of HFA- 
BDP is lower than that currently recommended. It was 
chosen on the basis that previous studies demon- 
strated an improved delivery of drug to the lower air- 
ways with this formulation, as a result of the smaller 
droplet size of HFA-BDP compared with CFCBDP 
suspension particles. The expectation that HFA-BDP 
would achieve efficacy at lower doses than CFC-BDP 
has been borne out in direct comparative studies. For 
example, in a study by Davies et al. (12), 12 weeks’ 
treatment with HFA-BDP 800 ug day-1 resulted in an 
equivalent change in morning PEF to treatment with 
CFC-BDP 1500 ,ug day-i. 
As a consequence of the reformulation of BDP 
in HFA, the drug is now evenly distributed in the 
solution and can be delivered in extrafine droplets 
when the propellant evaporates. Each strength of 
inhaler delivers the same proportion of the total dose. 
In the present study, treatment with 400 pg day-i 
HFA-BDP from either a 50 ug per actuation inhaler 
or a 100 ug per actuation inhaler resulted in equivalent 
asthma control, showing that the pharmaceutical and 
pharmacokinetic proportionality can be translated 
into clinical efficacy. 
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A greater proportion of the drug is delivered to the 
lungs with the HFA-BDP formulation, so less is 
deposited in the oropharynx (3). Oral candidiasis and 
hoarseness, which have been associated with inhaled 
steroid therapy (13), were reported by few patients in 
this study, although a spacer device was not used. No 
patient reporting an oropharyngeal adverse event was 
found to have Candida growth exceeding normal flora 
in cultures of mouth or throat swabs. 
In conclusion, treatment with HFA-BDP 
400 pg day-l was more effective than placebo in 
improving asthma control. The clinical efficacy of this 
dose was equivalent whether delivered from a 50 pg 
per actuation inhaler or a 100 pg per actuation inhaler. 
The safety profiles were similar for each study treat- 
ment, and they were both well tolerated without the 
use of a spacer. 
4. 
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